4 Questions About PsAID vs RAPID3 in Psoriatic Arthritis

It is important for rheumatologists to understand the validity of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire and the Routine Assessment of Patient Index Data (RAPID3) for use among patients with psoriatic arthritis (PsA).

In a new study, Alexis Ogdie-Beatty, MD, MSCE, an associate professor of medicine and epidemiology at the Perelman School of Medicine at the University of Pennsylvania, and colleagues evaluated data of 401 patients enrolled in the Psoriatic Arthritis Research Consortium between 2014 and 2016 to compare the 2 measurement tools.

The findings indicated that the PsAID and RAPID3 measures were highly correlated. The two measurement tools were also correlated with Short Form 12-Physical Component Summary and the Functional Assessment of Chronic Illness Therapy-Fatigue Scale.

Rheumatology Consultant caught up with Dr Ogdie-Beatty about the research.

Rheumatology Consultant: What prompted you to conduct the study?

Alexis Ogdie-Beatty: PsAID is a new measurement tool that has been validated for use in PsA. RAPID3 is a more commonly used tool across diseases in rheumatology, but it has also been validated for use in PsA. We wanted to know how closely the two measurement tools were correlated, and if they could be used interchangeably.

RHEUM CON: Was there a particular finding from the study that surprised you?

AOB: I was surprised at how strongly the two measurement tools were correlated despite having very different questions on the instruments.

RHEUM CON: Why is it important for rheumatologists to understand the validity of the RAPID3 and PsAID?

AOB: Understanding what affects the scores of both tools and what each tool is measuring is important for practicing rheumatologists. Overall, we found that both are essentially measuring the same thing. Contextual factors, including the presence of depression, obesity, enthesitis, joint counts, education, and insurance type, should be considered when interpreting raw scores of the RAPID3 and PsAID.

RHEUM CON: Are there any other validation tests that can be used in PsA?

AOB: There are other promising measures that can be used, but they have not yet been validated in PsA. We are also currently in the process of examining which instruments measure change in disease activity best.

Reference:

Walsh JA, Wan MT, Willinger C, et al. Measuring outcomes in psoriatic arthritis: comparing Routine Assessment of Patient Index Data (RAPID3) and Psoriatic Arthritis Impact of Disease (PSAID) [published online October 1, 2019]. J Rheumatol. doi:10.3899/jrheum.190219.

For more on PsA, visit the Center of Excellence.